febit's next-generation DNA sequencing paves the way for
23 March 2009
febit has launched its new DNA sequence-capture
technology HybSelect. febit says that several biomedical
studies conducted by customers with early access to
HybSelect have demonstrated superb enrichment factors and
deep sequencing coverage for a broad range of human genes
and genomic regions.
The sequence capture technology combines outstanding enrichment
and walk-away convenience, and opens up new opportunities in biomarker
discovery and the development of personalized medicine.
Declining costs and dramatically higher sequencing output has
distinguished the fast-paced genomics market since 2003. Sequencing a
human genome, a project that required years and billions of dollars, is
now feasible in weeks for thousands of dollars. Nevertheless, conducting
statistically relevant biomedical studies with deep sequencing of
patient samples is still prohibitively expensive and inefficient.
HybSelect effectively scales next-generation sequencing to the needs
of biomedical research and discovery by enabling large-scale studies.
The accessibility and enormous capacity of the next generation
sequencers have triggered a heightened demand for sequence capture
technologies amongst geneticists: targeted re-sequencing of
medically-relevant genome loci will greatly enhance the understanding of
health and disease in crucial areas such as cancer and Alzheimer's
The outcomes of such studies are significant in that they will allow
improved diagnostics and targeted applications of medical agents.
Peer Staehler, CSO of febit, summarized the advances of febit's
latest product: "HybSelect even enables large scale targeted
re-sequencing studies because of the high degree of automation combined
with the power to detect genetically relevant information in the genome
with high efficiency, which can not be met by PCR, or other methods on
"The fully automated HybSelect technology will compel adoption in
several ways: short hands-on time (minutes instead of hours), a high
degree of reproducibility, and unmatched parallelism in hybselecting
several genomic samples at a time."
The proof of concept has been positively confirmed by early access
customers. Dr Matthew Huentelman, an investigator and lead collaborator
at the Translational Genomics Research Institute (TGen) in Phoenix, AZ,
was one of the first researchers to use HybSelect.
His laboratory uses state-of-the-art techniques to pin-point
differences in genes and pathways that contribute to the development and
progression of Alzheimer's disease. "We are really excited about the
high enrichment factor and the depth of coverage of the targeted
sequences that can be achieved using HybSelect from febit. The short
hands-on time and ease of use reinforce our intentions to use this new
technology for further studies," said Dr. Huentelman.
HybSelect will also be employed in the newly developed Biomarker
Discovery Center Heidelberg for the detection of novel tumour markers.
Within the European READNA-consortium (Revolutionary Approaches and
Devices for Nucleic Acid analysis) HybSelect will support the selection
and enrichment of specific gene loci for next generation sequencers.
The new technology is available as a protocol for febit's Geniom RT
Analyzer, or as a full service including Next-Gen sequencing from febit.
HybSelect is optimized for the Illumina GAII sequencing system, and will
be available for other sequencing platforms soon.
Bookmark this page